Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Everolimus Oral Tablet Clear all
Terminated Phase 2 Interventional Results available

Everolimus in Treating Cutaneous T-cell Lymphoma

NCT01637090
View directory record Official record
Conditions
Cutaneous T-Cell Lymphoma
Interventions
Everolimus
Drug
Lead sponsor
Adam Lerner
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 29, 2026, 5:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

NCT04195750
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Everolimus
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • La Jolla, California • Santa Rosa, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma

NCT00827359
View directory record Official record
Conditions
Renal Cell Carcinoma, Renal Cancer
Interventions
Everolimus
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

NCT00570921
View directory record Official record
Conditions
Breast Cancer
Interventions
Everolimus, Fulvestrant
Drug
Lead sponsor
Mara Chambers
Other
Eligibility
45 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 29, 2026, 5:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965
View directory record Official record
Conditions
Breast Cancer
Interventions
PF-07248144, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
102
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

NCT00529802
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
RAD001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Chicago, Illinois • Peoria, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)

NCT00789828
View directory record Official record
Conditions
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Interventions
Everolimus, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

NCT00942734
View directory record Official record
Conditions
Head And Neck Cancer
Interventions
Erlotinib, RAD001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)

NCT01289912
View directory record Official record
Conditions
Tuberous Sclerosis Complex
Interventions
RAD001, Placebo
Drug
Lead sponsor
Mustafa Sahin
Other
Eligibility
6 Years to 21 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 1 Interventional

Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas

NCT02900716
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, B-Cell Lymphoma
Interventions
DTRMWXHS-12, DTRM-505, DTRM-555
Drug
Lead sponsor
Zhejiang DTRM Biopharma
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

NCT00251004
View directory record Official record
Conditions
Kidney Transplantation, Graft Rejection
Interventions
Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA), Basiliximab, Corticosteroids
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

NCT00410124
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
RAD001, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
31
States / cities
Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

NCT00107237
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
AEE788, everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 29, 2026, 5:14 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 29, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

NCT02560012
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Sunitinib, Temsirolimus, Sorafenib, Pazopanib, Everolimus, Axitinib
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

NCT01698918
View directory record Official record
Conditions
Hormone Receptor Positive Breast Cancer
Interventions
Everolimus, Letrozole, Exemestane, Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study), Standard of care to treat stomatitis (Stomatitis sub-study)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Gilbert, Arizona • Loma Linda, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 29, 2026, 5:14 AM EDT
Terminated Phase 2 Interventional Results available

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

NCT01048723
View directory record Official record
Conditions
Sarcoma
Interventions
RAD001
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 29, 2026, 5:14 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Belzutifan, Fulvestrant, Everolimus, Exemestane
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
14
States / cities
Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors

NCT02599324
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
Interventions
ibrutinib, everolimus, paclitaxel, docetaxel, cetuximab, pembrolizumab
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
44
States / cities
Huntsville, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT01797523
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Metformin, Letrozole, Everolimus
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
6
States / cities
Pensacola, Florida • Voorhees Township, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Early Phase 1 Interventional

Everolimus Trial in Laryngotracheal Stenosis

NCT05153668
View directory record Official record
Conditions
Idiopathic Subglottic Tracheal Stenosis
Interventions
Everolimus Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 29, 2026, 5:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

NCT00300274
View directory record Official record
Conditions
Graft Rejection
Interventions
everolimus, mycophenolate mofetil, cyclosporine, corticosteroids
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Sep 29, 2026, 5:14 AM EDT
Terminated Phase 1 Interventional Results available

A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

NCT01115803
View directory record Official record
Conditions
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
Interventions
LY2584702, Erlotinib, Everolimus
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 29, 2026, 5:14 AM EDT